Steven Cohen Amicus Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,266,900 shares of FOLD stock, worth $12.2 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

1,266,900

Holding current value

$12.2 Million

% of portfolio

0.04%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$9.55 - $12.09 $12.1 Million - $15.3 Million	1,266,900 New	1,266,900 $13.5 Million
Q3 2023 Nov 14, 2023	SELL	$11.78 - $13.86 $71.3 Million - $83.9 Million	-6,054,203 Reduced 86.48%	946,697 $11.5 Million
Q2 2023 Aug 14, 2023	BUY	$10.72 - $13.3 $50.9 Million - $63.2 Million	4,751,772 Added 211.27%	7,000,900 $87.9 Million
Q1 2023 May 15, 2023	BUY	$10.91 - $13.54 $24.5 Million - $30.5 Million	2,249,128 New	2,249,128 $24.9 Million
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $5.19 Million - $6.74 Million	528,500 Added 47.28%	1,646,400 $17.2 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $11.12 $4 Million - $7.14 Million	642,400 Added 135.1%	1,117,900 $12 Million
Q1 2022 May 16, 2022	BUY	$7.89 - $12.48 $3.75 Million - $5.93 Million	475,500 New	475,500 $4.5 Million
Q3 2021 Nov 15, 2021	SELL	$8.74 - $11.84 $33.8 Million - $45.8 Million	-3,867,400 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.71 - $10.72 $32.1 Million - $39.6 Million	3,690,078 Added 2081.0%	3,867,400 $37.3 Million
Q1 2021 May 17, 2021	BUY	$9.2 - $23.86 $1.63 Million - $4.23 Million	177,322 New	177,322 $1.75 Million
Q4 2020 Feb 16, 2021	SELL	$13.47 - $24.89 $20.8 Million - $38.4 Million	-1,541,042 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$12.89 - $15.89 $6.74 Million - $8.3 Million	522,513 Added 51.3%	1,541,042 $21.8 Million
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $10.8 Million - $19.2 Million	-1,224,371 Reduced 54.59%	1,018,529 $15.4 Million
Q1 2020 May 15, 2020	BUY	$6.63 - $11.16 $14.9 Million - $25 Million	2,242,900 New	2,242,900 $20.7 Million
Q4 2019 Feb 14, 2020	SELL	$7.48 - $10.75 $9.48 Million - $13.6 Million	-1,267,000 Closed	0 $0
Q3 2019 Nov 15, 2019	SELL	$8.02 - $13.25 $14.1 Million - $23.3 Million	-1,758,664 Reduced 58.12%	1,267,000 $10.2 Million
Q2 2019 Aug 14, 2019	BUY	$10.96 - $14.4 $33.2 Million - $43.6 Million	3,025,664 New	3,025,664 $37.8 Million
Q1 2019 May 15, 2019	SELL	$10.04 - $13.92 $38.2 Million - $52.9 Million	-3,800,585 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$8.38 - $13.44 $12.3 Million - $19.8 Million	1,471,385 Added 63.17%	3,800,585 $36.4 Million
Q3 2018 Nov 14, 2018	BUY	$11.6 - $16.54 $18.8 Million - $26.8 Million	1,621,900 Added 229.31%	2,329,200 $28.2 Million
Q2 2018 Aug 14, 2018	BUY	$13.13 - $17.09 $9.29 Million - $12.1 Million	707,300 New	707,300 $11 Million
Q1 2018 May 15, 2018	SELL	$13.76 - $17.12 $39.5 Million - $49.1 Million	-2,870,100 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$12.51 - $16.24 $14.1 Million - $18.4 Million	1,130,654 Added 65.0%	2,870,100 $41.3 Million
Q3 2017 Nov 14, 2017	BUY	$11.74 - $15.78 $20.4 Million - $27.4 Million	1,739,446	1,739,446 $26.2 Million

Others Institutions Holding FOLD

# of Institutions

313

Shares Held

314M

Call Options Held

516K

Put Options Held

833K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.71B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account